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Abstract
Introduction. Ticagrelor is the newest P2Y12 inhibitor recommended as the first treatment option for acute myocardial 
infarction both with and without ST-segment elevation. Recent studies have revealed unsatisfactory use of novel P2Y12 
inhibitors. The aim of our study was to assess the contemporary use of ticagrelor in major medical centres located in 
Kuyavian-Pomeranian, Pomeranian, and Warmian-Masurian voivodships.
Materials and methods. Retrospective analysis of hospital records regarding the number of ticagrelor tablets purcha-
sed monthly was performed covering a three-year period from January 2015 to December 2017. Data from 15 major 
medical centres was analysed.
Results. A total of 78,871 tablets of ticagrelor were purchased over the study period, with a monthly median of 2,013.5 
and an interquartile range (IQR) of 1,255–2,996. The amount of ticagrelor increased monthly by 7.9%. The lowest 
monthly value (294, 0.37%) was recorded in the first month, while the highest (4,550, 5.77%) was in October 2017. 
The median of tablets purchased in 2017 (3,934, IQR 3,010–4,270) was over four times greater than in 2015 (980, 
IQR 728–1,288, p < 0.001) and more than double that in 2016 (1,689, IQR 1,353–2,479, p = 0.012). The highest 
reported amount of the drug in one centre (16,296, 20.6%) was 291 times greater than the amount in the centre with 
the lowest ticagrelor use (56, 0.07%, p = 0.27).
Conclusions. The use of ticagrelor has been significantly increasing in recent years, which reflects the implementation 
of current guidelines by medical centres. Substantial heterogeneity regarding the use of ticagrelor is observed within 
particular centres.
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Introduction
Ticagrelor, cyclopentyl-triazolopyrimidine, is the newest 
oral P2Y12 inhibitor; it was approved for use in Europe in 
2010 [1]. Unlike thienopyridines, ticagrelor binds to a P2Y12 
receptor and causes conformational changes providing 
reversible inhibition of ADP-induced platelet aggregation 
[2]. Furthermore, this drug does not require liver metabo-
lism as it is already an active drug with additional active 
metabolite and rapid onset of platelet inhibition. Ticagrelor 
is less vulnerable to gene polymorphism compared to clo-
pidogrel. However, the effectiveness of platelet inhibition 
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Monthly purchase of ticagrelor was expressed as a total 
number of ticagrelor tablets. Based on the amount of the 
drug purchased monthly, we evaluated the variation of 
ticagrelor use over time. Each year and month of the study 
period was compared to the others regarding the amount 
of purchased drug. An analysis of ticagrelor use within par-
ticular centres was also performed. Continuous variables 
were presented as median with interquartile range (IQR), 
and categorical as absolute counts and percentages. 
Shapiro-Wilk test was performed to determine normality 
of the distribution. The Kruskal-Wallis and Mann-Whitney 
tests were used for comparison of more than two and two 
variables respectively. The trend line was calculated using 
the three-period moving average. A p-value of less than 
0.05 was considered statistically significant. Statistical 
analysis was performed using IBM SPSS software.
Results
A total of 78,871 tablets of ticagrelor were purchased over 
the study period. The cost of ticagrelor oscillated around 
590,000 PLN. Median of ticagrelor purchased monthly was 
2,013.5 with IQR: 1,255–2,996. The amount of ticagrelor 
noticeably increased over the three years. The dynamic 
growth during that period is illustrated by the red trend 
line (Figure 1).
During the first month of the observation, four medical 
centres purchased a total of 294 tablets (0.37%) of ticagre-
lor. The highest monthly amount of ticagrelor was recorded 
in October 2017. In that month,11 centres together acquired 
4,550 tablets (5.77%). Thus the amount of the drug incre-
ased by over 1,447% between the months with the lowest 
and the highest values of purchased ticagrelor (p = 0.006).
Over the study period, the amount of ticagrelor incre-
ased by an average of 7.9% each month. The increased 
use of the novel P2Y12 inhibitor is also noticeable in a year-
-to-year comparison (Figure 2). The median of ticagrelor 
tablets purchased in 2017 was over four times greater than 
in 2015 (3,934, IQR 3,010–4,270 vs 980, IQR 728–1,288, 
p < 0.001) and over two times greater than in 2016 (3,934, 
IQR 3,010–4,270 vs 1,689, IQR 1,353–2,479, p = 0.012). 
A pairwise comparison between the years 2015 and 
2016 did not reach statistical significance (p = 0.515).
Our results revealed a significant (p < 0.001) diversity 
in ticagrelor use within the medical centres (Figure 3). 
Three hospitals purchased more than 11,000 tablets du-
ring the study period. The amount of ticagrelor purchased 
by those centres covered 50.3% of the total value, with 
the median significantly higher than the median of the 
remaining 12 centres (11,984, IQR: 11,704–14,140 vs 
2,380, IQR 560–5,460, p = 0.004). Despite the signifi-
cant differences within all the centres, post-hoc analysis 
did not reveal a significant result for pairwise comparison 
still can be affected by external causes e.g. administration 
of morphine [3, 4] or type of myocardial infarction [5, 6]. 
Ticagrelor is contraindicated in patients with a history of 
intracranial haemorrhage or ongoing bleeding. Risk of dysp-
noea, ventricular pauses, and increased uric acid should be 
taken into consideration before starting the treatment [7].
Previous European guidelines for the management 
of patients with myocardial infarction with ST-segment 
elevation (STEMI) highlighted the role of newer oral P2Y12 in-
hibitors, and recommended ticagrelor and prasugrel as 
preferable to clopidogrel for periprocedural antithrombotic 
treatment in a primary percutaneous intervention (class 
IB) and for dual antiplatelet therapy with aspirin (class IA) 
[8]. Recent guidelines on the same subject have supported 
previous recommendations with improvement to the level of 
evidence for both indications [9]. Despite the more potent 
platelet inhibition achieved with ticagrelor and prasugrel, 
there is still a place for clopidogrel as it is recommended 
for patients treated with fibrinolysis and triple antiplatelet 
therapy as an addition to aspirin and oral anticoagulation 
[9]. Ticagrelor is also preferred for patients with acute 
coronary syndromes without ST-segment elevation (NSTE-
-ACS) both for conservative and invasive initial treatment 
strategy in the absence of contraindications (class IB) [10].
The current guidelines, as already mentioned, underline 
the importance of ticagrelor in the treatment strategy of 
patients with acute coronary syndromes (ACS). Previous 
studies indicated that higher adherence to existing guide-
lines is associated with better results [11]. Furthermore, 
adherence to appropriate treatment after ACS could result 
in decreased costs to healthcare systems [12]. Contempo-
rary use of the novel P2Y12 inhibitors has been proven to be 
unsatisfactory, with a persistently high rate of clopidogrel 
use [13].
The aim of our study was to assess the contemporary 
use of ticagrelor in major medical centres located in Kuya-
vian-Pomeranian, Pomeranian, and Warmian-Masurian 
voivodships.
Material and methods
A retrospective analysis of hospital records regarding the 
number of ticagrelor tablets purchased monthly was per-
formed covering a three-year period from January 2015 
to December 2017. A request to provide data regarding 
monthly ticagrelor use was sent to 20 major medical cen-
tres: 13 located in Kuyavian-Pomeranian Voivodship, six 
in Pomeranian Voivodship, and one in Warmian-Masurian 
Voivodship. A total of 5 centres were excluded — three did 
not respond to the request, one was incapable of disclosing 
the exact amount of the drug, and in one centre ticagrelor, 
in general, was not used. Data from the remaining 15 cen-
tres was further analysed.
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Figure 1. Total amount of ticagrelor purchased each month between January 2015 and December 2017 with marked trend line (red), 
p = 0.35
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Figure 2. Comparison of ticagrelor use between each year of ob-
servation. The median value is represented by the line inside the 
box, the interquartile range is denoted by the top and the bottom 
edge of the rectangle, and whiskers represent the minimum and 
the maximum value. One outlier observed in 2015 is marked with 
a circle; overall p < 0.01; 2015 vs 2016, p = 0.515; 2015 vs 2017, 
p < 0.001; 2016 vs 2017, p = 0.012
between the unit with the highest reported amount of the 
drug (16,296 tablets, 20.6%) and the lowest (56 tablets, 
0.07%, p = 0.27). However, the first-mentioned absolute 
value was 291 times greater than the latter.
Discussion
The crucial finding of our research is that the use of 
ticagrelor is constantly increasing, although noticeable 
differences were observed between particular medical cen-
tres. The positive trend observed in our study could reflect 
the implementation of the newest guidelines by medical 
centers to improve the results. The adaptation to the new 
treatment strategies could probably be more effective, but 
it is worth mentioning that novel P2Y12 inhibitors (ticagrelor 
and prasugrel) are not reimbursed in Poland for patients 
with acute coronary syndromes. Thus, medical centres are 
forced to choose between cheaper and older clopidogrel 
or more expensive newer drugs.
A recently published Polish study on a large group of 
patients (n = 19,437) diagnosed with STEMI and treated 
with primary PCI reported clopidogrel to be the most com-
monly used P2Y12 inhibitor (69%), with still low overall use 
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of novel drugs: 10.1% and 1.1% treated with ticagrelor and 
prasugrel respectively [13]. The authors found also a much 
higher percentage of pre-procedural than periprocedural 
administration of clopidogrel, while these proportions 
were inverted for ticagrelor. Other European registries also 
report a still high rate of patients diagnosed with STEMI 
or NSTE-ACS and treated with clopidogrel. In the APATHY 
registry [14], over half of the patients with ACS received 
clopidogrel (52%), a quarter prasugrel (25.5%), and less 
than a quarter ticagrelor (22.5%). De Luca et al. [15] repor-
ted that clopidogrel was prescribed at discharge for almost 
half of the patients (47.5%) diagnosed with NSTE-ACS and 
treated with PCI, while 42.8% received ticagrelor and only 
8.3% prasugrel. For STEMI patients treated with PCI those 
proportions were different in favour of novel P2Y12 inhibitors 
— ticagrelor, prasugrel, and clopidogrel were prescribed 
for 38.2%, 29.1%, and 32.1% respectively. More recent 
data from an Austrian registry revealed an improvement 
in the use of newer drugs in ACS patients treated with PCI 
[16]. Ticagrelor was prescribed for over 38% of patients 
at discharge (24.2% with STEMI, 52.3% with NSTE-ACS), 
prasugrel for one-third of patients (54.8% with STEMI, 
11.2% with NSTE-ACS), and clopidogrel for 27.2% (18.7% 
with STEMI, 35.9% with NSTE-ACS). Alexopoulos et al. [17] 
reported that clopidogrel was appropriately prescribed at 
discharge only in 23.8% of cases, whereas in over three-
-quarters it was a less preferable option. On the other hand, 
novel P2Y12 inhibitors, when selected, were in most cases 
prescribed appropriately (almost 90% for both ticagrelor 
and prasugrel).
The role of newer P2Y12 inhibitors is crucial during 
prehospital, inhospital, and after-discharge treatment 
of patients. In recently published recommendations for 
medical emergency teams [18], it was underlined that 
ticagrelor should be the preferred P2Y12 inhibitor in patients 
without contraindications and diagnosed with STEMI or 
very high-risk NSTE-ACS. Ticagrelor seems to have several 
advantages over prasugrel regarding the prehospital phase 
of antiplatelet treatment. Firstly, it can be administered to 
a wider spectrum of patients, as it has fewer contraindi-
cations. Furthermore, prasugrel is not recommended for 
NSTE-ACS patients with an unknown coronary anatomy. In 
everyday practice, a knowledge of the coronary anatomy 
is usually inaccessible for medical emergency teams. 
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Figure 3. Total amount of ticagrelor tablets purchased by particular medical centres. Each letter (A–N) refers to one particular medical 
centre included in the analysis; overall p < 0.001
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Thirdly, ticagrelor is preferred over prasugrel in prehospital 
treatment due to Polish legal regulations. Paramedics in 
Poland after sending ECG and consulting the cardiologist 
are allowed to administer on their own only clopidogrel 
and ticagrelor.
Clopidogrel compared to newer P2Y12 inhibitors has 
fewer contraindications e.g. it can be administered to 
patients already treated with an oral anticoagulation or 
with a history of previous intracranial bleeding [18]. How-
ever, the presence of contraindications along with the 
higher purchase cost of the novel drugs may not explain 
the higher usage of clopidogrel in medical centres in Po-
land. Patients treated with ticagrelor or prasugrel were 
more likely to be younger males with a lower prevalence 
of chronic obstructive pulmonary disease [13]. Prescrip-
tion of ticagrelor at discharge was also associated with 
lower GRACE score and lower bleeding risk [19]. Probably, 
more efficient education regarding P2Y12 inhibitors for 
physicians along with other medical professions (para-
medics, nurses etc.) could improve the use of ticagrelor 
or prasugrel and in so doing improve adherence to the 
newest guidelines.
The use of ticagrelor, as the reflection of the guideli-
nes adherence, should increase because of its beneficial 
effect, especially in the prehospital phase. Ticagrelor, as 
a novel P2Y12 inhibitor, has been investigated in many 
previous studies regarding for instance the administration 
of crushed tablets to overcome previously described drug-
-to-drug interactions with morphine [20]. Furthermore, it is 
necessary to determine the appropriate dose of ticagrelor 
in patients with acute myocardial infarction to optimise 
treatment and reduce adverse events [21]. It is indisputably 
necessary to further investigate ticagrelor, as well as other 
innovative drugs like cangrelor (intravenous P2Y12 inhibitor), 
in order to improve the results of treatment strategies in 
ACS patients [22].
We are aware of several limitations of this study. Firstly, 
we describe only an absolute value of ticagrelor purcha-
sed in various medical centres without adjustment for the 
number of patients treated in a particular centre and their 
diagnosis (i.e. STEMI vs NSTE-ACS). Furthermore, we provi-
de no information regarding other P2Y12 inhibitors. However, 
the aim of our study was to present the contemporary use 
of ticagrelor and its change over a three-year time period. 
Assuming that the number of patients treated in analysed 
centres did not increase drastically during the observation 
period, we do believe that our results could fairly reflect 
adherence to the newest guidelines regarding ticagrelor 
use in patients with STEMI or NSTE-ACS.
Conclusions
The use of the newest oral P2Y12 inhibitor (ticagrelor) has 
been systematically increasing in the past few years. Ob-
served trends could reflect the implementation of current 
guidelines by medical centres. Substantial heterogeneity 
within particular centres can still be observed regarding the 
use of ticagrelor, with differences reaching 291 times more 
ticagrelor purchased by one centre compared to another. 
Such differences indicate the need for a greater effort to 
improve the adherence to antiplatelet treatment guidelines, 
and to eliminate the existing differences between regional 
medical centres.
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Streszczenie
Wstęp. Tikagrelor to najnowszy doustny inhibitor receptora P2Y12 zalecany w leczeniu pierwszego rzutu w zawale serca 
zarówno z uniesieniem, jak i bez uniesienia odcinka ST. Ostatnie doniesienia wskazują na niezadowalające wykorzysta-
nie w terapii nowych inhibitorów receptora P2Y12. Celem niniejszego badania była ocena współczesnego wykorzystania 
tikagreloru w głównych ośrodkach medycznych zlokalizowanych na terenie województw kujawsko-pomorskiego, pomor-
skiego oraz warmińsko-mazurskiego.
Materiały i metody. Przeprowadzono retrospektywną analizę danych pochodzących ze szpitalnych rejestrów, które 
dotyczyły miesięcznej liczby zakupionych tabletek tikagreloru. Badanie obejmowało okres 3 lat — od stycznia 2015 do 
grudnia 2017 roku. Przeanalizowano dane pochodzące z 15 ośrodków medycznych.
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Wyniki. W trakcie okresu obserwacji kupiono w sumie 78 871 tabletek tikagreloru, a miesięczna mediana wyniosła 
2013,5 z przedziałem międzykwartylowym (IQR) 1255–2996. Ilość wykorzystywanego tikagreloru wzrastała miesięcznie 
o 7,9%. Najmniejszą ilość leku zarejestrowano w pierwszym miesiącu obserwacji (294; 0,37%), natomiast najwięcej tab-
letek (4550; 5,77%) kupiono w październiku 2017 roku. Mediana ilości tikagreloru w roku 2017 (3934, IQR 3010–4270) 
była ponad 4-krotnie większa od mediany w roku 2015 (980; IQR 728–1288; p < 0,001) i ponad 2-krotnie większa od 
zaobserwowanej w 2016 roku (1689; IQR 1353–2479; p = 0,012). Ośrodek, w którym odnotowano największą suma-
ryczną ilość zastosowanego tikagreloru (16 296; 20,6%), kupił w całym okresie obserwacji 291 razy więcej tabletek niż 
ośrodek z najmniejszą zarejestrowaną ilością leku (56; 0,07%; p = 0,27).
Wnioski. Wykorzystanie tikagreloru istotnie się zwiększyło w ostatnich latach, co odzwierciedla wprowadzanie do 
codziennej praktyki klinicznej zaleceń obecnych w aktualnych wytycznych dotyczących leczenia przeciwpłytkowego. 
Obserwuje się znaczne zróżnicowanie pod względem użycia tikagreloru w poszczególnych ośrodkach.
Słowa kluczowe: tikagrelor, inhibitory receptora P2Y12, stosowanie wytycznych
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